Management of patients with peripheral arterial disease in primary care: A cross-sectional study in Germany

International Journal of Clinical Practice

Volumn 64, Issue 7, 2010, Pages 875-884

  Kroger K ^a   Schwertfeger, M ^b   Pittrow, D ^c   Diehm, C ^d  

^a HELIOS KLINIKUM KREFELD   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUFLOMEDIL; CILOSTAZOL; CLOPIDOGREL; COUMARIN DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GINKGO BILOBA EXTRACT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NAFTIDROFURYL; PENTOXIFYLLINE; PROSTAGLANDIN; WARFARIN;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; GERMANY; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK FACTOR; SMOKING;

ADULT; AGED; AGED, 80 AND OVER; ARTERIOSCLEROSIS; CARDIOVASCULAR AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS;

EID: 77952689872     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02337.x     Document Type: Article

References (31)

1. Muller-Nordhorn J, Binting S, Roll S, Willich SN. An update on regional variation in cardiovascular mortality within Europe. Eur Heart J 2008 29: 1316 1326.
2. Federal Statistical Office. Leading causes for death in 2007. https://www-ec.destatis.de/csp/shop/sfg/bpm.html.cms.cBroker.cls?cmspath= struktur,vollanzeige.csp&ID=1022599 (accessed January 2010).
3. Daviglus ML, Lloyd-Jones DM, Pirzada A. Preventing cardiovascular disease in the 21st century: therapeutic and preventive implications of current evidence. Am J Cardiovasc Drugs 2006 6: 87 101.
4. Pearson TA. The prevention of cardiovascular disease: have we really made progress? Health Aff 2007 26: 49 60.
5. Greenland P, Abrams J, Aurigemma GP et al. Prevention Conference V. Beyond secondary prevention: Identifying the high-risk patient for primary prevention. Noninvasive tests of atherosclerotic burden. Circulation 2000 101: E16 22.
6. D'Agostino RB Sr., Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001 286: 180 187.
7. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) Study. Circulation 2002 105: 310 315.
8. Conroy RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003 24: 987 1003.
9. Silber S, Jarre F, Pittrow D et al. Cardiovascular risk assessment by primary-care physicians in germany and its lack of agreement with the established risk scores (DETECT). Med Klin (Munich) 2008 103: 638 645.
10. Diehm C, Schuster A, Allenberg JR et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 2004 172: 95 105. (Pubitemid 38058606) (Pubitemid 38058606)
11. Heald CL, Fowkes FG, Murray GD, Price JF. Risk of mortality and cardiovascular disease associated with the ankle-brachial index: Systematic review. Atherosclerosis 2006 189: 61 9.
12. Hirsch AT, Haskal Z, Hertzer N et al. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation 2006 113: 463 654.
13. Norgren L, Hiatt W, Dormandy J, Nehler M, Harris K, Fowkes F. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007 33 (Suppl. 1 S1 75.
14. Lawall H, Diehm C, Pittrow D (eds Deutsche Gesellschaft für Angiologie, Gesellschaft für Gefäßmedizin. S3-Leitlinien zur Diagnostik und Therapie der arteriellen Verschlusskrankheit. April 2009. http://www.uni-duesseldorf.de/AWMF/ll/065-003.pdf (accessed January 2010).
15. Khan NA, Rahim SA, Anand SS, Simel DL, Panju A. Does the clinical examination predict lower extremity peripheral arterial disease? JAMA 2006 295: 536 546.
16. Fleiss J, Cohen J. The equivalence of weighted kappa and the intraclass correlation coefficient as measures of reliability. Educ Psychol Meas 1973 33: 613 619.
17. Aronow WS, Ahn C. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age. Am J Cardiol 1994 74: 64 5.
18. Hirsch AT, Halverson SL, Treat-Jacobson D et al. The Minnesota Regional Peripheral Arterial Disease Screening Program: toward a definition of community standards of care. Vasc Med 2001 6: 87 96.
19. Hirsch AT, Criqui MH, Treat-Jacobson D et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001 286: 1317 1324.
20. Tepohl G, Trampisch HJ, Diehm C et al. Hohe Prävalenz der peripheren arteriellen Verschlußkrankheit in der Hausarztpraxis. Ergebnisse der getABI Studie. Cardiovasc 2003 7: 16 20.
21. Belch JJF, Topol EJ, Agnelli G et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003 163: 884 892.
22. Diehm C, Schwertfeger M, Tepohl G, Kirch W, Pittrow D. Versorgung von Patienten mit peripherer arterieller Verschlusskrankheit bei niedergelassenen Ärzten: eine aktuelle Bestandsaufnahme. Gefäßmedizin 2008 1: 4 13.
23. Regensteiner JG, Ware JE Jr., McCarthy WJ et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002 50: 1939 1946.
24. De Backer TL, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database Syst Rev 2008 April 16, CD001368.
25. Bongard V, Cambou JP, Lezorovcz A et al. Comparison of cardiovascular risk factors and drug use in 14,544 French patients with a history of myocardial infarction, ischaemic stroke and/or peripheral arterial disease. Eur J Cardiovasc Prev Rehabil 2004 11: 394 402.
26. Ohman EM, Bhatt DL, Steg PG et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 2006 151: 786 e1 10.
27. Pittrow D, Trampisch HJ, Paar WD et al. Gravierende Unterschiede in der medikamentösen Versorgung: PAVK-Patienten im Vergleich zu KHK-Patienten deutlich benachteiligt. Cardiovasc 2007 5: 36 9.
28. Anand S, Yusuf S, Xie C et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007 357: 217 227.
29. Johnson WC, Williford WO. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg 2002 35: 413 421.
30. Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction. J Am Coll Cardiol 2007 50: e1 157.
31. Luepker RV, Apple FS, Christenson RH et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies. A statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation 2003 108: 2543 2549.